感染

订阅

MedSci主页 / 所有栏目 / 感染

FDA将瑞德西韦的紧急使用授权扩大到所有COVID-19住院患者

2020-08-31 Allan MedSci原创

瑞德西韦Covid-19紧急使用授权（EUA）
关注

FDA扩大了吉利德科学公司Veklury（瑞德西韦）的现有紧急使用授权（EUA）的范围，以对所有怀疑或实验室确认的COVID-19住院患者进行治疗，且无论其疾病严重程度如何。III期ACTT试验的初步

FDA扩大了吉利德科学公司Veklury（瑞德西韦）的现有紧急使用授权（EUA）的范围，以对所有怀疑或实验室确认的COVID-19住院患者进行治疗，且无论其疾病严重程度如何。III期ACTT试验的初步结果表明，瑞德西韦组患者的平均恢复时间缩短了四天，瑞德西韦于5月获得了FDA的批准，可用于重症COVID-19患者。

吉利德首席医学官Merdad Parsey评论说：“扩大后的授权使医生能够更广泛地使用瑞德西韦。随着我们对COVID-19的了解越来越多，我们进一步确认了Veklury的功效和安全性”。

除ACTT试验外，另一项名为SIMPLE的研究发现，接受Veklury五天疗程加标准护理的中度COVID-19肺炎患者在第11天获得显著的临床改善。但是，10天疗程改善的几率与标准护理无明显差异。SIMPLE研究结果最近发表在《JAMA》上。

FDA的结论是，Veklury的已知和潜在利益超过了潜在风险，FDA有理由相信Veklury可以对所有COVID-19住院患者有效。

 

原始出处：

https://www.firstwordpharma.com/node/1753287?tsid=4

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=882015, encodeId=265888201535, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Wed Sep 02 08:07:37 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523307, encodeId=ec38152330e77, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Wed Sep 02 04:16:32 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881624, encodeId=1f71881624c7, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Sep 01 08:03:48 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881344, encodeId=1125881344b2, content=jama不是说对中度COVID-19没有明显疗效吗<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>🤔, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210607/9f00a0de660e4b36b77a9a5f7620d6bf/98c22b17ddf7446fa7b9a618fabcb9f7.jpg, createdBy=a8fb2299762, createdName=Psycho.Dr Du, createdTime=Mon Aug 31 14:43:45 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881332, encodeId=9f4488133202, content=如何改善支持治疗质量也应该是研究方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/480e12f811f44bc39b347d2521d56e86/67d0e6d503124ea685205b567af3dffd.jpg, createdBy=f9435296193, createdName=Baodongxu, createdTime=Mon Aug 31 14:05:32 CST 2020, time=2020-08-31, status=1, ipAttribution=)]
    2020-09-02 14818eb4m67暂无昵称

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=882015, encodeId=265888201535, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Wed Sep 02 08:07:37 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523307, encodeId=ec38152330e77, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Wed Sep 02 04:16:32 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881624, encodeId=1f71881624c7, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Sep 01 08:03:48 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881344, encodeId=1125881344b2, content=jama不是说对中度COVID-19没有明显疗效吗<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>🤔, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210607/9f00a0de660e4b36b77a9a5f7620d6bf/98c22b17ddf7446fa7b9a618fabcb9f7.jpg, createdBy=a8fb2299762, createdName=Psycho.Dr Du, createdTime=Mon Aug 31 14:43:45 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881332, encodeId=9f4488133202, content=如何改善支持治疗质量也应该是研究方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/480e12f811f44bc39b347d2521d56e86/67d0e6d503124ea685205b567af3dffd.jpg, createdBy=f9435296193, createdName=Baodongxu, createdTime=Mon Aug 31 14:05:32 CST 2020, time=2020-08-31, status=1, ipAttribution=)]
    2020-09-02 guguangxiang

    #紧急#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=882015, encodeId=265888201535, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Wed Sep 02 08:07:37 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523307, encodeId=ec38152330e77, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Wed Sep 02 04:16:32 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881624, encodeId=1f71881624c7, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Sep 01 08:03:48 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881344, encodeId=1125881344b2, content=jama不是说对中度COVID-19没有明显疗效吗<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>🤔, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210607/9f00a0de660e4b36b77a9a5f7620d6bf/98c22b17ddf7446fa7b9a618fabcb9f7.jpg, createdBy=a8fb2299762, createdName=Psycho.Dr Du, createdTime=Mon Aug 31 14:43:45 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881332, encodeId=9f4488133202, content=如何改善支持治疗质量也应该是研究方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/480e12f811f44bc39b347d2521d56e86/67d0e6d503124ea685205b567af3dffd.jpg, createdBy=f9435296193, createdName=Baodongxu, createdTime=Mon Aug 31 14:05:32 CST 2020, time=2020-08-31, status=1, ipAttribution=)]
    2020-09-01 14818eb4m67暂无昵称

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=882015, encodeId=265888201535, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Wed Sep 02 08:07:37 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523307, encodeId=ec38152330e77, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Wed Sep 02 04:16:32 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881624, encodeId=1f71881624c7, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Sep 01 08:03:48 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881344, encodeId=1125881344b2, content=jama不是说对中度COVID-19没有明显疗效吗<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>🤔, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210607/9f00a0de660e4b36b77a9a5f7620d6bf/98c22b17ddf7446fa7b9a618fabcb9f7.jpg, createdBy=a8fb2299762, createdName=Psycho.Dr Du, createdTime=Mon Aug 31 14:43:45 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881332, encodeId=9f4488133202, content=如何改善支持治疗质量也应该是研究方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/480e12f811f44bc39b347d2521d56e86/67d0e6d503124ea685205b567af3dffd.jpg, createdBy=f9435296193, createdName=Baodongxu, createdTime=Mon Aug 31 14:05:32 CST 2020, time=2020-08-31, status=1, ipAttribution=)]
    2020-08-31 Psycho.Dr Du

    jama不是说对中度COVID-19没有明显疗效吗#新冠肺炎#🤔

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=882015, encodeId=265888201535, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Wed Sep 02 08:07:37 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523307, encodeId=ec38152330e77, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Wed Sep 02 04:16:32 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881624, encodeId=1f71881624c7, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Sep 01 08:03:48 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881344, encodeId=1125881344b2, content=jama不是说对中度COVID-19没有明显疗效吗<a href='/topic/show?id=46ce580e865' target=_blank style='color:#2F92EE;'>#新冠肺炎#</a>🤔, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58078, encryptionId=46ce580e865, topicName=新冠肺炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210607/9f00a0de660e4b36b77a9a5f7620d6bf/98c22b17ddf7446fa7b9a618fabcb9f7.jpg, createdBy=a8fb2299762, createdName=Psycho.Dr Du, createdTime=Mon Aug 31 14:43:45 CST 2020, time=2020-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881332, encodeId=9f4488133202, content=如何改善支持治疗质量也应该是研究方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210315/480e12f811f44bc39b347d2521d56e86/67d0e6d503124ea685205b567af3dffd.jpg, createdBy=f9435296193, createdName=Baodongxu, createdTime=Mon Aug 31 14:05:32 CST 2020, time=2020-08-31, status=1, ipAttribution=)]
    2020-08-31 Baodongxu

    如何改善支持治疗质量也应该是研究方向

    0

相关资讯

吉利德在发达国家将COVID-19治疗药物瑞德西韦的价格定为每瓶390美元

瑞德西韦（Remdesivir）是由美国吉利德（Gilead）科学公司开发的一种新型实验性广谱抗病毒药物，用来针对埃博拉病毒及被认为可以有效抑制呼吸道上皮细胞中SARS病毒和MERS病毒的复制。

Nature：瑞德西韦对感染新冠的猕猴的临床益处

用瑞德西韦治疗的动物没有表现出呼吸系统疾病的迹象，并且在第一次治疗给药后12小时，X光片上的肺部浸润减少，支气管肺泡灌洗液中的病毒滴度降低。

BMJ：新冠肺炎药物治疗的有效性研究

与标准护理相比，糖皮质激素可能降低covid-19患者的死亡率和机械通气风险。大多数干预措施的有效性尚不确定

JAMA：瑞德西韦似乎对中度新冠肺炎没有明显治疗效果

近期《美国医学会杂志》(JAMA)的一份研究指出，瑞德西韦似乎对中度新冠肺炎患者没有明显治疗效果，与此前对瑞德西韦的报告结果不一致。

Cell Discov：海藻提取物比瑞德西韦更有效抑制SARS-CoV-2

在对导致COVID-19的病毒的抗病毒效果的测试中，一种从食用海藻中提取的物质大大超过了目前用于对抗这种疾病的标准抗病毒药物瑞德西韦。

美国国立卫生研究院（NIH）进行瑞德西韦联合干扰素β-1a治疗COVID-19的临床试验

美国国立卫生研究院（NIH）已开始进行一项随机对照临床试验，以评估抗病毒药物瑞德西韦联合免疫调节剂干扰素β-1a治疗COVID-19的安全性和有效性（ACTT 3研究）。

拓展阅读

WHO推荐用于新冠重症救治的巴瑞替尼，你至少需要知道这4点！

1、具有住院高危因素的患者：强烈推荐使用（奈玛特韦片/利托那韦）；弱推荐使用（莫努匹韦）（瑞德西韦）。2、重型或危重型患者：强烈推荐使用糖皮质激素、IL-6受体阻断剂、巴瑞替尼，而且这三种药物可以联用

NEJM：BQ.1.1和XBB对小分子抗新冠病毒药物仍然敏感

新冠病毒BQ.1.1 和 XBB 对目前已知上市的单抗类药物全部耐药，但是，对小分子抗新冠病毒药物是否敏感呢？最新一期《新英格兰杂志》上报道了相关研究。

FDA宣布：准瑞德西韦用于治疗28天以上幼童的新冠病毒感染的治疗！

美国时间4月25日，食品暨药物管理局（FDA）首次正式批准，吉利德医药公司（Gilead）生产的COVID－19（2019冠状病毒疾病）治疗药物瑞德西韦（Remdesivir）可用于出生28天以上的幼

Infection：瑞德西韦在 COVID-19 住院患者中的疗效和安全性分析

瑞德西韦（Remdesivir），是一种核苷类似物，具有抗病毒活性，后来经批准可用于新冠肺炎的治疗。

NEJM：瑞德西韦治疗可预防Covid-19门诊患者病情进展

在Covid-19进展风险较高的非住院患者中，瑞德西韦治疗3天的安全性可接受，与安慰剂相比，住院或死亡风险降低了87%。

NEJM：早期瑞德西韦治疗可使新冠肺炎患者住院风险降低87%

对于存在重症高风险因素的非住院新冠肺炎患者，3天的瑞德西韦治疗方案可有效降低患者住院风险，较安慰剂相比，风险下降了87%。